AKRO
Akero Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 1
consensus rating "Strong Buy"
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About AKRO
Akero Therapeutics, Inc.
A clinical-stage company that develops transformational treatments for serious metabolic diseases
601 Gateway Boulevard, Suite 350, South San Francisco, CA 94080
--
Akero Therapeutics, Inc., was incorporated under the laws of the State of Delaware in January 2017. The Company is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. The company's initial focus was on non-alcoholic steatohepatitis, or NASH, a disease for which there are no approved therapies. NASH is a serious non-alcoholic fatty liver disease, or NAFLD, characterized by inflammation and fibrosis of the liver, which can progress to cirrhosis, liver failure, cancer and death. NASH is the leading cause of liver transplantation. The company's lead product candidate, AKR-001, which is being developed as a potential treatment for NASH patients, is an analog of fibroblast growth factor 21, or FGF21. FGF 21 is an endogenously expressed hormone that regulates the metabolism of lipids, carbohydrates and proteins throughout the body. FGF21 also plays a key role in protecting many types of cells from various forms of stress.
Company Financials
EPS
AKRO has released its 2024 Q4 earnings. EPS was reported at -0.99, versus the expected -1.12, beating expectations. The chart below visualizes how AKRO has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
